Physician

Justin Leonadus Yancey, D.O.

According to 2025 Medicare claims, Justin Yancey, D.O. (NPI: 1013390467) practices nephrology in the Memphis, TN-MS-AR market, with the plurality of this provider's patient population coming from De Soto, MS. This provider's primary affiliated billing organization is MID-SOUTH NEPHROLOGY CONSULTANTS PLLC (NPI: 1346219342; TIN: 621650432) and primary practice location at 38671-4739. Yancey is affiliated with the Connected Care, LLC (ACO ID: A5709), participating under the MSSP model.

Yancey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 849 traditional Medicare patients, billed 5,638 HCPCS/CPT codes, and received $368,720 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 755 prescription claims across 158 beneficiaries totaling $255,224 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 25 claims. Open Payments data shows 11 records totaling $368. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $27,766 to $368,720. Similarly, Part D prescription costs have risen steadily, from $2,643 to $255,224. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	192	403	$27,766
2021	452	1,712	$139,981
2022	420	2,075	$144,653
2023	838	3,737	$307,395
2024	849	5,638	$368,720

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	16	40	$2,643
2016	51	103	$2,936
2017	59	123	$5,356
2018	40	103	$24,728
2019	16	40	$719
2020	43	108	$3,338
2021	35	95	$4,562
2022	65	267	$39,836
2023	120	457	$186,772
2024	158	755	$255,224

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	26	$1,095
2022	N/R	30	$1,504
2023	N/R	N/R	N/R
2024	N/R	25	$365

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	231	275	$126
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	178	458	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	168	213	$60
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	477	1,521	$57
90935	Hemodialysis procedure with physician evaluation	184	637	$52

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	57	2,010	$172,041
Farxiga	Dapagliflozin Propanediol	43	1,905	$35,723
Sevelamer Carbonate	Sevelamer Carbonate	62	3,060	$19,716
Lokelma	Sodium Zirconium Cyclosilicate	13	492	$7,740
Midodrine Hcl	Midodrine Hcl	11	670	$829

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	11	$189
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$368	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Justin Leonadus Yancey, D.O.?

Tedicare shows public-source Medicare data for Justin Leonadus Yancey, D.O. (NPI 1013390467), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Justin Leonadus Yancey, D.O. have ACO affiliation data?

Justin Leonadus Yancey, D.O. is shown with ACO affiliation data for Connected Care, LLC (MSSP, ACO ID A5709).

What billing organization is linked to Justin Leonadus Yancey, D.O.?

Justin Leonadus Yancey, D.O. is linked to MID-SOUTH NEPHROLOGY CONSULTANTS PLLC (billing NPI 1346219342) in the available physician profile data.

Does Justin Leonadus Yancey, D.O. have Open Payments data?

Justin Leonadus Yancey, D.O. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.